Active Nanotargeting in Medicine

Piera       Di Martino

doi:10.2174/138161282517190822161247

[1] 
García-Couce J, Almirall A, Fuentes G, Kaijzel E, Chan A, Cruz LJ. Targeting polymeric nanobiomaterials as a platform for cartilage tissue engineering. Curr Pharm Des  2019; 25(17): 1915-32.
[2] 
Gigliobianco MR, Di Martino P, Deng S, Casadidio C, Censi R. New advanced strategies for the treatment of lysosomal diseases affecting the central nervous system. Curr Pharm Des  2019; 25(17): 1933-50.
[3] 
Gaspar N, Zambito G, Löwik CMWG, Mezzanotte L. Active targeting of macrophages. Curr Pharm Des  2019; 25(17): 1951-61.
[4] 
Iscaro A, Howard NF, Muthana M. Nanoparticles: properties and applications in cancer immunotherapy. Curr Pharm Des  2019; 25(17): 1962-79.
[5] 
Patras L, Banciu M. Intercellular crosstalk via extracellular vesicles in tumor milieu as emerging therapies for cancer progression. Curr Pharm Des  2019; 25(17): 1980-2006.
[6] 
Ding Y, Hong X, Liu Y, Zhang H. Recent advances in magnetic upconversion nanocomposites for bioapplications. Curr Pharm Des  2019; 25(17): 2007-15.

Download Options

Rights & Permissions Print Cite

Current Pharmaceutical Design

Title:Active Nanotargeting in Medicine

Volume: 25 Issue: 17

Author(s): Piera Di Martino

Affiliation:

Export Options

Export File:

RIS (for EndNote, Reference Manager, ProCite)

BibTeX

Text

Content:

Citation Only

Citation and Abstract

About this article

Cite this article as:

Di Martino Piera , Active Nanotargeting in Medicine , Current Pharmaceutical Design 2019; 25 (17) . https://dx.doi.org/10.2174/138161282517190822161247

DOI https://dx.doi.org/10.2174/138161282517190822161247	Print ISSN 1381-6128
Publisher Name Bentham Science Publisher	Online ISSN 1873-4286

About this journal

Call for Papers in Thematic Issues

Submission closes on : 31 December, 2025

Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.

This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more

Guest Editor(s): Dr. Manish Gautam

Submission closes on : 31 December, 2025

Blood-based biomarkers in large-scale screening for neurodegenerative diseases

Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more

Guest Editor(s): Dr. Carlo Cervellati

Submission closes on : 31 December, 2025

Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions

Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more

Guest Editor(s): Dr. Sidharth Mehan

Submission closes on : 31 December, 2025

Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine

Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more

Guest Editor(s): Dr. Ali Yadollahpour,